scholarly journals Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies

2021 ◽  
Vol 27 (35) ◽  
pp. 5890-5907
Author(s):  
Roberta Elisa Rossi ◽  
Alessandra Elvevi ◽  
Davide Citterio ◽  
Jorgelina Coppa ◽  
Pietro Invernizzi ◽  
...  
Author(s):  
J. C. Garancis ◽  
J. F. Kuzma ◽  
S. D. Wilson ◽  
E. H. Ellison

It has been proposed that a gastrin-like hormone elaborated by non-beta islet tumors of the pancreas may be responsible for a fulminating ulcer diathesis. Subsequently, a potent gastric secretagogue was isolated from ulcerogenic tumors of the pancreas. This disease process is known now as “Zollinger-Ellison syndrome”.In our studies of two cases of Zollinger-Ellison syndrome, pancreatic lesions were identified as alpha islet cell tumors (Fig. 1). Tumor cells were fairly uniform. The sizes of the alpha granules were not significantly different, but their number and distribution varied greatly from one cell to another. Each granule consisted of a round, highly dense central core, separated from the limiting membrane by an opaque zone. The granular form of the endoplasmic reticulum was particularly prominent. Numerous mitochondria, round or elongated, were dispersed throughout the cytoplasm. Individual or clusters of lysosomes were observed in the majority of cells.


2001 ◽  
Vol 120 (5) ◽  
pp. A613-A613
Author(s):  
P BORNMAN ◽  
K RADEBOLD ◽  
H DEBAERE ◽  
L VENTER ◽  
H HEINZE ◽  
...  

1964 ◽  
Vol 47 (2) ◽  
pp. 184-187 ◽  
Author(s):  
Brian A. Scobie ◽  
Douglas B. McGill ◽  
James T. Priestley ◽  
Randolph A. Rovelstad

1963 ◽  
Vol 44 (4) ◽  
pp. 512-518 ◽  
Author(s):  
L. Angervall ◽  
G. Dotevall ◽  
K.-E. Lehmann ◽  
P.B. Norberg

1999 ◽  
Vol 41 (6) ◽  
pp. 1173 ◽  
Author(s):  
Dong Jin Jung ◽  
Hyun Kwon Ha ◽  
Pyo Nyun Kim ◽  
Moon Gyu Lee ◽  
Yong Ho Auh

2010 ◽  
Vol 2 ◽  
pp. CMT.S4500
Author(s):  
B. Al-Judaibi ◽  
N. Chande ◽  
G.K. Dresser ◽  
N. Sultan ◽  
J.C. Gregor

Esomeprazole (S-omeprazole) is a single optical enantiomer proton-pump inhibitor (PPI) approved for the management of gastro-oesophageal reflux disease, the prevention and treatment of Non-Steroidal Anti-Inflammatory Drugs (NSAID) associated gastric ulcer disease, treatment of duodenal ulcer disease associated with Helicobacter pylori infection, and the treatment of Zollinger-Ellison syndrome. Esomeprazole has been shown to be safe and effective during pregnancy and was introduced to the market in 2001. PPI therapy may interact with clopidogrel by cytocrome 2C19. Clopidogrel is a prodrug which is partially activated by cytochrome 2C19 and esomeprazole is a competitive inhibitor of 2C19. Esomeprazole is more effective than other PPIs in controlling esophageal and gastric pH, but efficacy in symptom relief is less clear.


1966 ◽  
Vol 39 (463) ◽  
pp. 494-497 ◽  
Author(s):  
Hans Ludin ◽  
F. Enderlin ◽  
H. J. Fahrländer ◽  
S. Scheidegger

1994 ◽  
Vol 14 (4) ◽  
pp. 222
Author(s):  
Liu GT ◽  
Schatz NJ ◽  
Curtin VT ◽  
Tse DT

Sign in / Sign up

Export Citation Format

Share Document